Mitral Technologies is a MedTech company dedicated to the development of a novel device for the treatment of functional mitral valve regurgitation through mitral valve repair.
Mitral regurgitation occurs when the mitral valve leaflets do not close efficiently (when leaflets do not coapt correctly) and blood moves backwards to the left atrium instead of exiting the heart through the aorta. If left untreated, MR can cause heart failure.
Mitral Technologies device and procedure is anticipated to allow physicians to treat functional mitral regurgitation through a transcatheter procedure commonly used by interventional cardiologists. The learning curve for this new technology is expected to be minimal as it is based on cardiologist’s standard expertise.
MR is the most prevalent valvular heart disease in the community, its prevalence increasing along with population aging and heart failure.
Etiology of MR can be very diverse, and the mechanism of regurgitation is variable according to the underlying anatomo-functional lesions. Organic lesions are most commonly secondary to degeneration of connective tissue with localized or diffuse alterations of the annulus, leaflets, and chordae, leading to prolapsing lesions and annular dilatation. Beyond degenerative MR (DMR), organic MR can be of post-inflammatory, infective etiology, or associated to other rare diseases. In contrast, functional MR (FMR) is characterized by absence of structural lesions, and mitral insufficiency is due to sub-valvular and valvular deformations caused by left ventricular remodeling and dysfunction. FMR is due to myocardial infarction (MI). The natural history of severe MR is unfavorable, leading to left ventricular (LV) failure, atrial fibrillation, stroke, and death. FMR represents 66% of all MR in developed countries.
Mitral Technologies procedure allows physician to perform a anterio-posterior plasty of the mitral annulus. The procedure reduces A-P distance increasing leaflet coaptation pulling P2 towards A2. The procedure is performed through coronary sinus access followed by a puncture to access the left atrium. Following left atrium access, a puncture of the trigon allows an anchor to be positioned in the LVOT. A support structure is implanted in the coronary sinus and a wire, connecting the LVOT anchor and the coronary support, pulls P2 towards A2.
Mr. Rasschaert is a senior executive with over 25 years medical device experience in business development, and sales and marketing in the global market environment. He is a serial entrepreneur who has launched seven medical device start-up companies. Mr. Rasschaert’s first success took place in 1996 when Medtronic acquired InStent for $268 million. Mr. Rasschaert was part of the initial team who started InStent (coronary stents – Eden Prairie, MN) in 1992. He was instrumental in launching InStent worldwide operations. He was part of the initial team that started Timm Medical Technologies (urology products – Eden Prairie, MN) in 1998. Endocare successfully purchased Timm Medical Technologies in 2001. Then, Mr. Rasschaert co-foudned CardialCare (ventricular assist device – St Louis Park, MN). More recently, Mr. Rasschaert was the President and CEO and founder of Epitek (Left Atrial Appendage closure device – Bloomington, MN). Mr. Rasschaert launched Epitek in 2004 from scratch. Following Epitek’s exit, Mr. Rasschaert co-founded and raised capital for MitralFlex (adaptable annuloplasty ring – Lausanne, Switzerland). He then became the CEO in residence at Cormove, a French company developing a novel TAVR device (trans-aortic valve replacement – TAVR – Bornel, France). In 2017, Mr. Rasschaert co-founded Mitral Technologies. Mr. Rasschaert is the author of 13 medical device patents and provisional patents in the cardiovascular field.
Mr. Ravoet is a mechanical engineer. Mr. Ravoet has spent 27 years in the aerospace field as development engineer. From 2011 through 2017, Mr. Ravoet was the head of engineering at SABCA. The SABCA Group is one of the main aerospace and defense actors in Belgium, belonging to Dassault Group and Fokker Technologies (GKN Group). It is made up of SABCA S.A. and its subsidiaries SABCA Limburg and ASM Aéro, and conducts its operations from Belgium’s three regions (Brussels Capital Region, Gosselies in Wallonia, and Lummen in Flanders) as well as Casablanca, Morocco.
Mr. Gubernati has a bachelor’s degree in biomedical engineering from Politecnico, Torino, Italy. He began his career as an engineer with Elettricità Ramella and Ponderano. Later, Mr. Gubernati became responsible for the production line.
After a degree in Communication, Advertising and Public Relations, Mr. Ocula started his career at Amplycell as the Communication developer. Amplycell develops new techniques to increase recombinant proteins and monoclonal antibodies production. Then, Mr. Ocula worked as marketing manager for Sports Bar & Grill in London’s headquarter in the United Kingdom.